Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10040086 | 0.74 | KDM4E (0.36) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL12178905 | 0.65 | SMN1; SMN2 (0.37) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL12178890 | 0.63 | KDM4E (0.37) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL12178322 | 0.62 | SMN1; SMN2 (0.40) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL14151520 | 0.61 | KDM4E (0.33) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL9958507 | 0.59 | GAA (0.35) | KDM4EGAANPSR1 | |
| SCHEMBL27945121 | 0.58 | TSHR (0.32) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL14903885 | 0.57 | SMN1; SMN2 (0.37) | KDM4EGAAMEN1KMT2ANPSR1 | |
| SCHEMBL14151742 | 0.56 | SORD (0.33) | KDM4EGAA | |
| SCHEMBL20797472 | 0.56 | KDM4E (0.36) | KDM4EGAAMEN1KMT2ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130005775-A1 | METHODS OF TREATING ULCERATIVE COLITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2013-01-03 | — | — | US | disclosed |
| US-8093267-B2 | Methods of treating rheumatoid arthritis | LEXICON PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100113530-A1 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA | LEXICON PHARMACEUTICALS, INC. | 2010-05-06 | — | — | US | disclosed |
| US-20100076030-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS | LEXICON PHARMACEUTICALS, INC. (US) | 2010-03-25 | — | — | US | disclosed |
| US-7649098-B2 | Imidazole-based compounds, compositions comprising them and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-19 | — | — | US | disclosed |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113530-A1 | S1P LYASE INHIBITORS FOR THE TREATMENT OF CEREBRAL MALARIA | S1PR1, S1PR2, SPHK1 | KDM4E 1565/4885GAA 1095/4885MEN1 2252/4885 |
| US-20070208063-A1 | Imidazole-based compounds, compositions comprising them and methods of their use | TPMT, INMT, NFKBIA | KDM4E 2146/4885GAA 877/4885MEN1 1419/4885 |
| US-20100076030-A1 | METHODS OF TREATING RHEUMATOID ARTHRITIS | SSB, NFKBIA, MPO | KDM4E 3130/4885GAA 1053/4885MEN1 4596/4885 |
| US-20130005775-A1 | METHODS OF TREATING ULCERATIVE COLITIS | SI, S1PR2, SPHK2 | KDM4E 1186/4885GAA 895/4885MEN1 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.